Dr. Nancy Broitman Mozelsio, MD

Dr. Mozelsio practices at Allergy & Asthma Medical Group of Diablo Valley Inc in Walnut Creek, California.

Dr. Mozelsio's NPI, 1114910551, was assigned on August 30, 2005. Dr. Mozelsio graduated from UC Irvine School of Medicine in 1996. Dr. Mozelsio holds California license A75031.

Dr. Mozelsio's primary practice is Allergy & Asthma Medical Group of Diablo Valley Inc, at 370 N Wiget Ln, Walnut Creek, CA 94598 in Contra Costa County. The practice phone is (925) 935-6252.

Dr. Mozelsio's primary practice is Allergy & Asthma Medical Group of Diablo Valley Inc in Walnut Creek, California. Dr. Mozelsio is also affiliated with John Muir Medical Center, Walnut Creek. The medical group on file is Allergy & Asthma Medical Group of the Bay Area. Dmand AI also links Dr. Mozelsio to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mozelsio practices, 2 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Mozelsio's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Mozelsio is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Mozelsio's licenses on file in 2 states: California and Illinois.

Dmand AI lists asthma, chronic nasal allergies and hives among the conditions Dr. Mozelsio treats.

CMS data shows 3,737 Medicare services from Dr. Mozelsio across 12 procedure codes in 2024, for 221 Medicare patients. Medicare paid $61,599 for them. Every service was in an office.

CMS counts 221 Medicare patients who saw Dr. Mozelsio in 2024. The largest group is 65 to 74, with 124 patients. 75% of them have high cholesterol, and 56% have high blood pressure. 7% are also on Medicaid. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mozelsio's median patient age at 38, with 60% women.

In 2024, Dr. Mozelsio wrote 711 Medicare Part D claims for 182 patients. 68% of them were for generic drugs. CMS names the drug for 562 of them, across 16 drugs with 11 or more claims each, at $120,061 in total drug cost. In 2023, CMS named 590 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Mozelsio for performance year 2024, reported as part of a group. Dr. Mozelsio accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Mozelsio, published from 2020 to 2021. Dr. Mozelsio's most frequent co-authors are Karna Gendo, MD, Katherine Cleveland Gilbert, MD and Matthew John Lodewick, MD.

CMS Open Payments shows 175 general payments to Dr. Mozelsio from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $881.

Dmand AI lists 1 award for Dr. Mozelsio, most recently CMS Stage 1 EHR in 2013.

Dr. Mozelsio graduated from UC Irvine School of Medicine in 1996. Dr. Mozelsio is a member of AAAAI.

Dr. Mozelsio is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.